Journal of Law, Medicine and Ethics 41 (3):635-643 (2013)

Sergio Sismondo
Queen's University
The pharmaceutical industry, in its marketing efforts, often turns to “key opinion leaders” or “KOLs” to disseminate scientific information. Drawing on the author's fieldwork, this article documents and examines the use of KOLs in pharmaceutical companies’ marketing efforts. Partly due to the use of KOLs, a small number of companies with well-defined and narrow interests have inordinate influence over how medical knowledge is produced, circulated, and consumed. The issue here, as in many other cases of institutional corruption, is that a few actors have accumulated the power to shape the information on which many others base their decisions. Efforts to address this corruption should focus on correcting large imbalances in the current political economy of medical knowledge. A sequestration of pharmaceutical research and development on one hand from pharmaceutical marketing on the other, though difficult to achieve, would address this and many other problems
Keywords No keywords specified (fix it)
Categories (categorize this paper)
DOI 10.1111/jlme.12073
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy

Upload a copy of this paper     Check publisher's policy     Papers currently archived: 57,156
Through your library

References found in this work BETA

View all 9 references / Add more references

Citations of this work BETA

View all 21 citations / Add more citations

Similar books and articles

Five Un‐Easy Pieces of Pharmaceutical Policy Reform.Marc A. Rodwin - 2013 - Journal of Law, Medicine and Ethics 41 (3):581-589.


Added to PP index

Total views
28 ( #371,338 of 2,411,732 )

Recent downloads (6 months)
1 ( #539,061 of 2,411,732 )

How can I increase my downloads?


My notes